Market Overview

UPDATE: Jefferies Upgrades Vanda Pharmaceuticals to Buy on Tasimelteon Catalyst

Share:
Related VNDA
Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%
Benzinga's Top Upgrades, Downgrades For May 26, 2017

Jefferies upgraded Vanda Pharmaceuticals (NASDAQ: VNDA) from Hold to Buy and raised the price target from $3.50 to $6.00.

Jefferies commented, "We're finally giving credit for tasimelteon given 1) surprisingly good recent Non24 Ph.3 data w/clinical sleep efficacy which likely improves FDA receptivity, 2) orphan pricing not confounded by ‘depression' efforts, and 3) approaching regulatory catalysts. We still think it's far from a slam dunk, but even conservatively discounted Tasi contribution is likely big upside from current negative EV level."

Vanda Pharmaceuticals closed at $3.95 on Wednesday.

Latest Ratings for VNDA

DateFirmActionFromTo
May 2017H.C. WainwrightInitiates Coverage OnBuy
Apr 2017OppenheimerInitiates Coverage OnOutperform
Nov 2016Aegis CapitalInitiates Coverage OnBuy

View More Analyst Ratings for VNDA
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Analyst Ratings

 

Related Articles (VNDA)

View Comments and Join the Discussion!